PHTS patients have different breast cancer risks depending on their PTEN germline variant: truncating variants were associated with two to three times higher risks than missense variants, and variants located in the phosphatase domain were additionally associated with two times higher risks than variants in domain C2 [3]. This evidence concerns the gene PTEN and breast cancer.